Expressions and Clinicopathologic Signif icances of CA1929 and CA125 in Benign and Malignant Lesions of Gallbladder_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

L IU J ieqiong , YA N G Zhul in , MIAO X iongy in.

Research L aboratory of Hepatobi l iary and Pancreatic Diseases , The Second Xiangya Hospi al of Cent ral South Uni versi t y , Changsha 410011 , ChinaCorres ponding Author : YANG Zhul in , E-mai l : yangz hul in8 @sina. com;

Corresponding author：

Keywords：

Gallbladder adenocarcinoma ，Chronic cholecystitis ，Tumor marker

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

To study the expressions of CA19-9 and CA125 and their clinicopathologic significances
in gallbladder adenocarcinoma , pericancerous tissues and chronic cholecystitis. Methods 　EnVisionTM immunohistochemist ry was used for assaying the expressive levels of CA1929 and CA125 in the routinely paraffin2embedded sections of specimens f rom gallbladder adenocarcinoma ( n = 108) , pericancerous tissues ( n = 46) , and chronic cholecystitis ( n = 35) . Results 　The positive rates of CA19-9 and CA125 were significantly higher in gallbladder adenocarcinoma ( 49. 1 % , 51. 9 %) than those in pericancerous tissues ( 26. 1 % , 15. 2 %) and chronic cholecystitis
(14. 3 % , 5. 7 %) , respectively ( P lt; 0. 01) . The positive rates of CA19-9 and CA125 were significantly lower in the
cases of adenomatous canceration , maximal diameter lt; 2 cm , no-metastasis of lymph node and no-invasion of regional tissues than those in the ones of low-differentiated adenocarcinoma , maximal diameter ≥2 cm , metastasis of
lymph node and invasion of regional tissues ( P lt; 0. 05 , P lt; 0. 01 ) . The consistence of CA19-9 and CA125 expressive
levels was found in gallbladder adenocarcinoma (χ2 = 44. 69 , P lt; 0. 01) . Conclusion 　The expressions of CA19-9 and
CA125 may be important tumor markers to reflect the carcinogenesis , progression , biological behaviors and prognosis of gallbladder adenocarcinoma.

Citation： L IU J ieqiong,YA N G Zhul in,MIAO X iongy in.. Expressions and Clinicopathologic Signif icances of CA1929 and CA125 in Benign and Malignant Lesions of Gallbladder. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2008, 15(2): 92-95. doi: Copy

1.	<><><><><><><> [1]Passerini R,Riggio D,Salvatici M,et al.Interchangeability of measurements of CA19-9 in serum with four frequently used assays:an update[J].Clin Chem Lab Med,2007; 45(1):100.
2.	Locker GY,Hamilton S,Harris J,et al.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J].J Clin Oncol,2006; 24(33):5313.
3.	Hogdall EV,Christensen L,Kjaer SK,et al.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish "MALOVA" Ovarian Cancer Study[J].Gynecol Oncol,2007; 104(3):508.
4.	王兰君,李国兴,王秀民.卵巢癌和胰腺癌患者血清CA125、CA19-9的水平相关分析[J].放射免疫学杂志,2007; 20(1):68.
5.	Plemenos MF,Dimas C,Kotsios A,et al.Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma[J].J BUON,2004; 9(1):73.
6.	Kushitani K,Takeshima Y,Amatya VJ,et al.Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma[J].Pathol Int,2007; 57(4):190.
7.	Rosen DG,Wang L,Atkinson JN,et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol,2005; 99(2):267.
8.	Tornos C,Soslow R,Chen S,et al.Expression of WT1,CA 125,and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary[J].Am J Surg Pathol,2005; 29(11):1482.
9.	Howell NR,Zheng W,Cheng L,et al.Carcinomas of ovary and lung with clear cell features:can immunohistochemistry help in differential diagnosis?[J].Int J Gynecol Pathol,2007; 26(2):134.
10.	吴泓,熊先泽,程南生,等.胰腺囊腺癌的诊断(附36例报告)[J].中国普外基础与临床杂志,2005; 12(5):509.
11.	杨风辉,宫东尧.外周血糖链抗原CA50及CA19-9在大肠癌中的应用价值[J].中国普外基础与临床杂志,2002; 9(2):封二.
12.	Grote T,Logsdon CD.Progress on molecular markers of pancreatic cancer[J].Curr Opin Gastroenterol,2007; 23(5):508.
13.	Nagao K,Itoh Y,Fujita K,et al.Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes[J].Int J Urol,2007; 14(9):795.
14.	Shukla VK,Gurubachan,Sharma D,et al.Diagnostic value of serum CA242,CA19-9,CA15-3 and CA125 in patients with carcinoma of the gallbladder[J].Trop Gastroenterol,2006; 27(4):160.
15.	Bouanène H,Harrabi I,Ferchichi S,et al.Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer[J].Bull Cancer,2007; 94(7):E18.
16.	Lipská L,Visokai V,Levy M,et al.Tumor markers in patients with relapse of colorectal carcinoma[J].Anticancer Res,2007; 27(4A):1901.
17.	Kang CM,Kim JY,Choi GH,et al.The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer[J].J Surg Res,2007; 140(1):31.
18.	Bast RC Jr,Feeney M,Lazarus H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma[J].J Clin Invest,1981; 68(5):1331.
19.	Liu PY,Alberts DS,Monk BJ,et al.An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy[J].J Clin Oncol,2007; 25(24):3615.
20.	Tsao KC,Hong JH,Wu TL,et al.Elevation of CA19-9 and chromogranin A,in addition to CA125,are detectable in benign tumors in leiomyomas and endometriosis[J].J Clin Lab Anal,2007; 21(3):193.

1. <><><><><><><> [1]Passerini R,Riggio D,Salvatici M,et al.Interchangeability of measurements of CA19-9 in serum with four frequently used assays:an update[J].Clin Chem Lab Med,2007; 45(1):100.
2. Locker GY,Hamilton S,Harris J,et al.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J].J Clin Oncol,2006; 24(33):5313.
3. Hogdall EV,Christensen L,Kjaer SK,et al.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish "MALOVA" Ovarian Cancer Study[J].Gynecol Oncol,2007; 104(3):508.
4. 王兰君,李国兴,王秀民.卵巢癌和胰腺癌患者血清CA125、CA19-9的水平相关分析[J].放射免疫学杂志,2007; 20(1):68.
5. Plemenos MF,Dimas C,Kotsios A,et al.Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma[J].J BUON,2004; 9(1):73.
6. Kushitani K,Takeshima Y,Amatya VJ,et al.Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma[J].Pathol Int,2007; 57(4):190.
7. Rosen DG,Wang L,Atkinson JN,et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol,2005; 99(2):267.
8. Tornos C,Soslow R,Chen S,et al.Expression of WT1,CA 125,and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary[J].Am J Surg Pathol,2005; 29(11):1482.
9. Howell NR,Zheng W,Cheng L,et al.Carcinomas of ovary and lung with clear cell features:can immunohistochemistry help in differential diagnosis?[J].Int J Gynecol Pathol,2007; 26(2):134.
10. 吴泓,熊先泽,程南生,等.胰腺囊腺癌的诊断(附36例报告)[J].中国普外基础与临床杂志,2005; 12(5):509.
11. 杨风辉,宫东尧.外周血糖链抗原CA50及CA19-9在大肠癌中的应用价值[J].中国普外基础与临床杂志,2002; 9(2):封二.
12. Grote T,Logsdon CD.Progress on molecular markers of pancreatic cancer[J].Curr Opin Gastroenterol,2007; 23(5):508.
13. Nagao K,Itoh Y,Fujita K,et al.Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes[J].Int J Urol,2007; 14(9):795.
14. Shukla VK,Gurubachan,Sharma D,et al.Diagnostic value of serum CA242,CA19-9,CA15-3 and CA125 in patients with carcinoma of the gallbladder[J].Trop Gastroenterol,2006; 27(4):160.
15. Bouanène H,Harrabi I,Ferchichi S,et al.Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer[J].Bull Cancer,2007; 94(7):E18.
16. Lipská L,Visokai V,Levy M,et al.Tumor markers in patients with relapse of colorectal carcinoma[J].Anticancer Res,2007; 27(4A):1901.
17. Kang CM,Kim JY,Choi GH,et al.The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer[J].J Surg Res,2007; 140(1):31.
18. Bast RC Jr,Feeney M,Lazarus H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma[J].J Clin Invest,1981; 68(5):1331.
19. Liu PY,Alberts DS,Monk BJ,et al.An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy[J].J Clin Oncol,2007; 25(24):3615.
20. Tsao KC,Hong JH,Wu TL,et al.Elevation of CA19-9 and chromogranin A,in addition to CA125,are detectable in benign tumors in leiomyomas and endometriosis[J].J Clin Lab Anal,2007; 21(3):193.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions and Clinicopathologic Signif icances of CA1929 and CA125 in Benign and Malignant Lesions of Gallbladder

Abstract Full text Figures/Tables Video References Cited by

Format

Content